|
|
| Line 1: |
Line 1: |
| == Introduction ==
| | [[Image:PPI gif.gif]] |
|
| |
| | |
| [[Image:eso.jpg|300px|left|thumb|'''2D Structure & Biochemical Parameters of Esomeprazole''' Esomeprazole has two important pyridine and benzimidazole moieties linked through a methylenesulfinyl group. pKa, IC50, AUC, Cmax, and half life values of Esomeprazole.
| |
| ]]'''Esomeprazole''' is the (S) enantiomer of Omeprazole. Esomperazole is a '''Proton Pump Inhibitor (PPI)''' that binds to '''H+/K+-ATPase''' and inhibits the secretion of gastric acid from parietal cells into the lumen of the stomach. Esomeprazole’s commercial brand name, Nexium, is used to treat Gastro-esophageal Reflux Disease (GERD), peptic and gastric ulcers, and Zollinger-Ellison syndrome.<ref name="one">[Mayo Clinic. Esomeprazole (Oral Route). http://www.mayoclinic.com/health/drug-information/DR603283 (accessed November 11, 2013).]</ref>
| |
| Ulcers caused by the bacterium ''Helicobacter pylori'' can be treated using Esomeprazole in conjunction with proper antibiotics.<ref name="one"/> Gastric acid is released through the H+/K+-ATPase pump, which is the final step in acid release. <ref name="two">[National Institutes of Health: DailyMed. NEXIUM (Esomeprazole magnesium) capsule, delayed release [A-S Medication Solutions LLC]. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9af7a792-d38a-4b2a-b5d6-855d2183b029 (accessed November 11, 2013).]</ref> Esomeprazole is a specific, irreversible inhibitor of the pump. <ref name="two">
| |
|
| |
| [[Image:PPI gif.gif]]
| |
|
| |
|
| == H+/K+-ATPase == | | == H+/K+-ATPase == |